337
edits
Changes
Jump to navigation
Jump to search
no edit summary
<textblock> This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can attenuation of ACTH release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in CAH. </textblock>
</detailed_description>
<overall_status>Completed</overall_status> <phase>Phase 1/Phase 2</phase> <study_type>Interventional</study_type> <study_design>Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design> <condition>Congenital Adrenal Hyperplasia</condition>
==== Location ====
The corresponding node is:
